Brunadol

Quick links to important sections

Brunadol

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Brunadol

Property Description
Active Ingredients Acetaminophen and Naproxen Sodium
Pharmacological Class Analgesic, Antipyretic, Nonsteroidal Anti-Inflammatory Drug (NSAID)
Form Oral tablets, caplets, or suspension
Common Use Pain relief and fever reduction
Origin Synthetic

Brunadol is a fixed-dose combination medication containing two distinct active ingredients: Acetaminophen (or Paracetamol) and Naproxen Sodium. This dual composition places the product into overlapping pharmacological categories, primarily functioning as a combined Analgesic (pain reliever) and Antipyretic (fever reducer).

The inclusion of Naproxen Sodium means the medication incorporates a Nonsteroidal Anti-Inflammatory Drug (NSAID). Both Acetaminophen, an aminophenol derivative, and Naproxen Sodium are chemically synthetic compounds, contributing distinct and complementary physiological actions to the preparation. The two agents together represent a non-opioid approach to managing discomfort, a feature that is clinically recognized for effective management of common, temporary pain.

The medicine is manufactured for the oral route of administration, commonly supplied in drug forms such as tablets and caplets, with certain preparations also available as a liquid suspension. The availability of liquid forms is a distinguishing factor that allows for administration to a broader target audience, including patients who experience difficulty swallowing solid preparations. These variations in pharmaceutical preparation are designed to ensure effective delivery.

General Purpose of the Dual-Action Combination

The general purpose of the Brunadol combination is to provide enhanced relief for minor aches and pains and effective fever reduction by utilizing two separate mechanisms of effect. Combining agents with different actions, such as a centrally acting analgesic like Acetaminophen and a peripherally acting anti-inflammatory like Naproxen Sodium, offers additive pain-relieving activity. This means that the combination generally works better for relief than taking either drug alone. Furthermore, the combination is used in pain management due to the efficacy of NSAIDs combined with Acetaminophen for general analgesia.

Regulatory References

  1. MedlinePlus Drug Information on Naproxen

What side effects are possible with Brunadol?

Possible Side Effects and Safety Information

The official safety profile for Brunadol, a combination of Acetaminophen and Naproxen Sodium, is structured by regulatory authorities to classify potential adverse reactions across various physiological systems and established frequency categories.

System-Organ Classes and Common Adverse Reactions

Adverse reactions are formally grouped by the affected organ system, primarily involving Gastrointestinal Disorders, Nervous System Disorders, Cardiac and Vascular Disorders, and Skin and Subcutaneous Tissue Disorders. According to regulatory data for the naproxen component, the most common documented reactions include dyspepsia, abdominal pain, nausea, headache, rash, and edema.

Serious Adverse Reactions

Official labeling emphasizes the potential for serious, life-threatening events associated with the active components. These include Serious Cardiovascular Thrombotic Events such as myocardial infarction and stroke, which may occur early in treatment and increase with the duration of use. The medicine also carries risks of Acute Liver Failure (associated with the acetaminophen component) and serious Gastrointestinal Bleeding, Ulceration, and Perforation.

Safety Restrictions and Population Considerations

The official safety profile includes several restrictions. The medicine is contraindicated in patients with a history of allergic reactions to NSAIDs, and in the setting of Coronary Artery Bypass Graft (CABG) surgery. Older patients are documented as being at greater risk for serious gastrointestinal and cardiovascular adverse events. Furthermore, the NSAID component requires avoidance during late-stage pregnancy (starting at 30 weeks gestation) due to documented fetal risks.

Overdose and Emergency Response

Overdose and When to Seek Help

Brunadol overdose involves a Dual-Agent Toxicity Profile, presenting risks associated with both Acetaminophen and Naproxen Sodium. Symptoms may include nausea, vomiting, abdominal pain, drowsiness, dizziness, or, critically, no initial symptoms at all. Severe manifestations can involve tinnitus, severe headache, and confusion.


Serious Outcomes and Emergency Action

The overdose profile includes two primary areas of severe toxicity:

  • The Acetaminophen component carries the risk of severe liver damage (hepatotoxicity), acute liver failure, and potential death.
  • The Naproxen Sodium component carries the risk of serious gastrointestinal bleeding, acute kidney failure, seizures, and altered mental status.

Regulatory authorities mandate that if an overdose is suspected, individuals must seek immediate medical attention or contact a Poison Control Center right away. Immediate medical assistance is required even if there are no noticeable symptoms, as severe toxicity can have a delayed onset. Medical providers will monitor vital signs and perform laboratory assessments of hepatic and renal function.

N-acetylcysteine (NAC) is the specific antidote available for the acetaminophen component. For the naproxen component, no specific antidote is known, and management is strictly symptomatic and supportive. Risk of severe outcomes is higher in individuals with pre-existing liver disease or kidney disease, and in older adults.

Therapeutic Uses of Brunadol

What Brunadol Treats: Main Uses and Benefits

Brunadol is applied across domains where additional symptomatic support is needed, primarily for symptoms related to physical discomfort and systemic imbalance. Medications like this are commonly used in settings marked by temporary physiological imbalance. It helps address symptom clusters that may become intense or disruptive, and generally provides symptomatic assistance.

Relief for Inflammatory and Musculoskeletal Pain

This category is relevant for easing discomfort, stiffness, and swelling associated with joint and soft tissue conditions. Brunadol is relevant in clinical settings marked by heightened patient distress from conditions involving inflammatory or irritative processes, such as osteoarthritis, rheumatoid arthritis, tendinitis, and bursitis. The medication generally contributes to comfort during periods of heightened symptoms that interfere with daily functioning. The combination is commonly used across conditions presenting with acute episodes, including headaches, migraine, toothaches, menstrual cramps, and general body aches.

“This therapeutic combination is relevant for easing symptoms related to physical discomfort, systemic imbalance, and inflammatory states.”

Management of Acute Symptoms and Discomfort

The combination is applied when symptoms create noticeable functional strain and is typically used in areas where short-term symptom management is appropriate, such as during seasonal illness or following minor dental work. This supportive approach assists with supporting functional stability and may help patients cope more steadily with symptom fluctuations. This relief contributes to easing day-to-day comfort during symptomatic periods by easing the overall symptom load.


Quick Fact: Relief for Acute and Chronic Discomfort

The medication may provide supportive assistance for both acute, intense pain (like headaches or toothaches) and the chronic discomfort linked to joint inflammation.

Regulatory References

  1. MedlinePlus Medical Encyclopedia overview on Pain Relievers

Eligibility and Restrictions for Use

Brunadol, a fixed-dose combination of acetaminophen and naproxen sodium, is subject to specific population eligibility rules defined by regulatory agencies.

Populations Who Must Not Use Brunadol (Contraindications)

Official labeling strictly prohibits use in certain groups due to safety risks:

  • Hypersensitivity: Patients with a known allergy to naproxen, acetaminophen, or any other Nonsteroidal Anti-Inflammatory Drug (NSAID), including those with aspirin-sensitive asthma.
  • Cardiovascular Surgery: Patients undergoing or immediately following coronary artery bypass graft (CABG) surgery.
  • Pregnancy (Third Trimester): Women at or after 30 weeks gestation.

Age and Organ Function Restrictions

Use is restricted or not established in other populations:

  • Pediatric Limits: Non-prescription use is not recommended for children under 12 years of age, and safety is not established for children under two years.
  • Older Adults (Age 60+): Use is associated with an increased risk of adverse effects, and regulators recommend initiating treatment with the lowest dose.
  • Renal/Cardiac Impairment: Use is not recommended in patients with advanced renal disease (CrCl < 30 mL/min). The medicine should be avoided in cases of severe heart failure.
  • Pregnancy (Conditional): Use between 20 and 30 weeks gestation requires limiting the dose and duration of treatment.

What should I know about interactions with other medicines?

Interactions with other Medicines and Products

Regulatory documentation confirms that co-administration of Brunadol with certain medicinal products and substances is subject to specific constraints due to the presence of both Acetaminophen and Naproxen Sodium (an NSAID).

Formally Contraindicated and Restricted Combinations

Classification Interacting Substance Official Constraint Description
Contraindicated Other Acetaminophen-containing products Co-administration is formally prohibited due to the severe, documented risk of liver damage.
Avoidance Other NSAIDs (e.g., Ibuprofen, other Naproxen products) Concurrent use should be avoided as it significantly increases the official risk of serious gastrointestinal adverse events, including bleeding.
Contraindicated Use near CABG Surgery The Naproxen component is strictly contraindicated in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Clinically Significant Pharmacodynamic and Pharmacokinetic Interactions

The Naproxen component may diminish the antihypertensive effect of co-administered medicines such as ACE Inhibitors, Angiotensin Receptor Blockers (ARBs), and certain Diuretics. This component also carries an additive risk of serious GI bleeding when co-administered with Oral Corticosteroids, Anticoagulants (like Warfarin), Antiplatelet Agents, and SSRIs/SNRIs.

  • Exposure Modification: Naproxen may increase the plasma concentrations of Lithium and Methotrexate by reducing their renal clearance. Conversely, the Acetaminophen absorption is reduced by Colestyramine; regulatory text requires that Colestyramine not be administered within 1 hour of the Acetaminophen component to prevent this reduction.

  • Metabolic Risk: Consumption of three or more alcoholic drinks per day is officially associated with a heightened risk of severe liver damage due to the Acetaminophen component.

Population-Specific Interaction Notes

Official labeling documents that the combination of the Naproxen component with ACE Inhibitors or ARBs carries an increased risk of renal function deterioration in specific populations, notably elderly patients, those who are volume-depleted, or patients with pre-existing renal impairment.

Mechanism of Action

Brunadol (a proprietary name for acetaminophen/paracetamol) is primarily a centrally acting agent that readily crosses the blood-brain barrier. Its principal actions modulate signaling within the central nervous system (CNS), with negligible peripheral effects. The core mechanism involves a non-competitive inhibitory interaction with the cyclooxygenase (COX) enzymes, specifically an inhibition of prostaglandin (PG) synthesis within the CNS, a process hypothesized to involve the peroxidase function of COX-1 and COX-2. This inhibition leads to a reduction in the central concentration of prostaglandin E2 ( PGE2).

Downstream, the drug's metabolite, N-acyl-phenolamine (AM404), contributes to the action by modulating various pathways. AM404 is an agonist at transient receptor potential vanilloid-1 ( TRPV1) receptors and also inhibits the reuptake of the endogenous cannabinoid anandamide, thereby increasing its local concentration and activating cannabinoid CB1 receptors centrally. Furthermore, Brunadol modifies the descending serotonergic pathway activity. The ultimate system-level physiological consequence is a direct modulation of the central processing of sensory signals and hypothalamic thermoregulatory set-point activity.

Dosage and Administration Information

How to Use Brunadol

Brunadol, a fixed-dose combination of acetaminophen and naproxen sodium, is administered via the oral route using the lowest effective dose for the shortest duration necessary. The administration protocol is defined by strict time intervals and maximum dose limits, rather than a fixed daily schedule.

Official Administration Guidelines

Administration Scope Detail and Parameters
Route of administration: Oral only (tablets, caplets, or liquid suspension form).
Dosing frequency: Typically taken on an intermittent basis, such as every 8 to 12 hours, strictly maintaining the maximum daily dose limits for both active components.
Timing in relation to meals: May be taken with or after food or milk to aid tolerance, but must always be taken with a full glass of water.
Preparation requirements: The liquid suspension requires a calibrated measuring device for accurate dose delivery. Solid forms must be swallowed whole.

Use Duration and Specific Populations

Standard protocols include duration limits for use without specialist oversight. For temporary acute pain relief, the use of Brunadol is generally restricted to a maximum of 10 consecutive days, and use for fever reduction is typically limited to a maximum of 3 consecutive days.

Regarding specific patient populations, the lowest effective dose is generally advised for older adults to manage risk. Additionally, patients with underlying renal or hepatic impairment may require dose reduction or avoidance of the medicine entirely. This structure ensures that administration remains aligned with standards for non-opioid pain management.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Brunadol

Brunadol, a fixed-dose combination of Acetaminophen and Naproxen Sodium, has been the subject of clinical evaluation. The primary research base includes Randomized Controlled Trials (RCTs) and systematic reviews. The existing research examined outcomes related to physical discomfort and patient-reported functional status.


Evidence for Use in Acute Pain and General Analgesia

Clinical research has heavily focused on symptom patterns in the context of acute, episodic pain. This research often utilizes RCTs comparing the combination to placebo in analgesic models, such as minor surgical or dental procedures. Studies monitored patient-reported outcomes describing perceived discomfort, including changes in measured pain intensity and patient-reported pain scales over defined time intervals. Findings describe patterns observed in these studies, where the combination was associated with changes in measured pain intensity compared to placebo.

However, the current evidence is mainly derived from analgesic models (like dental pain), meaning the results apply only to the populations studied. Comparative evidence is lacking for generalization across all acute pain types, and follow-up durations were limited (typically ten days or less).


Evidence for Use in Chronic Musculoskeletal Discomfort (Osteoarthritis)

Research was studied for conditions characterized by fluctuating or episodic manifestations such as osteoarthritis (OA). Studies examined outcomes reflecting daily functioning or activity level, as well as patient-reported scores for pain and stiffness. The evidence base includes synthesizing data from individual component trials, rather than relying solely on dedicated, large-scale trials of the fixed-dose combination itself in this setting. This contributes to the finding that evidence quality varies across studies.

Long-term effects are not fully established for the fixed combination when used regularly for chronic discomfort. The follow-up durations were limited for a condition that is long-lasting.


Evidence in Pediatric and Other Specific Populations

Research has observed the use of Brunadol in specific age groups, including adolescents (aged 12 to under 17 years), primarily through specialized pharmacokinetic (PK) studies to examine how the body processes the medication. Data for certain groups, such as older adults with complex health issues, remain insufficient, and research does not determine whether an individual will respond similarly.

Key Studies & References

  1. Naproxen/acetaminophen

Frequently Asked Questions (FAQ)

Common questions about Brunadol (FAQ)

Q: How quickly should I expect to feel the effects of Brunadol?

Studies on the Naproxen Sodium component indicate that it is absorbed rapidly after taking a dose. Peak concentrations in the blood are typically reached within 1 to 2 hours. This timeframe indicates when the therapeutic component typically reaches peak concentration in the body.

Q: Can Brunadol be taken long-term for chronic conditions?

Regulatory guidance emphasizes that this medication should be used for the shortest possible duration. For acute pain relief, use is often restricted to a maximum of 10 consecutive days. Because the risk of serious side effects may increase with extended use, official guidance indicates that long-term treatment requires oversight by a healthcare professional.

Q: Why do some people experience stomach upset when starting Brunadol?

Stomach upset, such as dyspepsia or abdominal pain, is a common documented reaction due to the Naproxen component, which belongs to the class of NSAIDs. Official warnings highlight a risk of serious gastrointestinal issues, including bleeding. The medication label mentions that taking the drug with food or milk may help aid tolerance and minimize potential stomach irritation.

Q: What is the typical duration of pain relief provided by one dose of Brunadol?

Official dosing guidelines recommend taking the medication on an intermittent basis, typically every 8 to 12 hours. This dosing frequency may offer an approximation of the relief period for some users, though individual results can vary.

Q: Can Brunadol affect my sleep cycle?

Official product labeling notes that central nervous system (CNS) adverse effects, such as headache, dizziness, and drowsiness, are possible. The possibility of CNS effects means that individuals may experience changes in their state of alertness or drowsiness.

Q: Is it normal to have a slight headache after starting Brunadol?

Yes, headache is listed as one of the commonly reported adverse reactions documented in official product labeling. Severe or persistent symptoms should always be discussed with a healthcare professional.

Q: Can Brunadol affect blood pressure readings?

Official warnings state that the medicine may cause new or worsen existing high blood pressure. Furthermore, the Naproxen component can reduce the effectiveness of other medications prescribed to lower blood pressure. Due to these risks, official regulatory guidance indicates that blood pressure should be closely monitored during treatment.

Q: Are there different forms of Brunadol (e.g., tablet, liquid, extended-release)?

Official labeling confirms the product is manufactured in forms such as oral tablets, caplets, and liquid suspension. Any additional specialized forms, such as extended-release preparations, would be specifically noted on the product label.

Q: What is the difference between the active and inactive ingredients in Brunadol tablets?

The active ingredients, Acetaminophen and Naproxen Sodium, are the components that produce the therapeutic effects of pain relief and fever reduction. The inactive ingredients, also listed on the official label, are components necessary for forming the tablet, but they do not contribute to the medicine’s effectiveness.

Q: What is the purpose of the coating on some Brunadol tablets?

Coatings are often added to tablets to protect the active ingredients from light and moisture and to make the tablet easier to swallow. The coating’s function is primarily noted for swallowing ease, stability, or to control the rate of release of the medication as described in the official product information.

Q: Can Brunadol be taken with antacids?

Some substances, such as Colestyramine, are known to reduce the absorption of the Acetaminophen component. Official regulatory guidance advises separating the administration of Colestyramine by at least one hour. For specific interaction concerns with other products, consulting the full product information is necessary.

Q: Are there any major diet restrictions while taking Brunadol?

The most important restriction noted in official warnings concerns alcohol consumption. Official warnings state that consuming three or more alcoholic drinks per day is formally associated with a heightened risk of severe liver damage due to the Acetaminophen component.

Q: How long does it usually take for Brunadol to clear a mild fever?

The fever-reducing component, Acetaminophen, is known to be rapidly absorbed by the body. Peak levels in the bloodstream are typically reached in 30 to 60 minutes, which is when the fever-reducing component typically starts to become available in the body.

Q: Is it okay to drive after taking Brunadol?

Because this medication may cause central nervous system side effects like dizziness and drowsiness, users are cautioned against engaging in activities that require mental alertness, such as driving or operating heavy machinery, until they know how the drug affects them.

Q: Can Brunadol cause changes in mood or anxiety levels?

Official labeling documents that the Naproxen component carries a potential for rare adverse reactions classified under 'Psychiatric Disorders,' which includes depression. The listing of psychiatric disorders as potential adverse reactions indicates a possible effect on a user’s overall emotional state.

Q: How does Brunadol target pain without numbing other sensations?

The drug works through a central mechanism, such as modulating the transmission of pain signals in the brain, rather than blocking nerve signals in the body. This is distinct from the action of local anesthetics, which cause 'numbing' by blocking nerve conduction.

How should Brunadol be stored and disposed of?

How to Store and Dispose of Brunadol

Brunadol (Acetaminophen and Naproxen Sodium) must be stored under specific conditions to maintain its effectiveness, as directed by official labeling.


Storage Requirements

Brunadol must be stored at Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F). The medicine must be protected from light and stored away from excessive heat above 40 C (104 F) and high humidity. It is required to store the medicine in its original container and carton.

Mandatory Safety: The product must always be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Brunadol should be disposed of via a drug take-back program or medicine disposal site when available. If not, follow the official household procedure: mix the medicine with an unappealing substance, seal it in a container, and place it in the trash. Do not flush the medicine down the toilet or pour it into a sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Brunadol found in:

A-Z Index: